ANTX

AN2 Therapeutics, Inc. (ANTX) | Rumor.io

AN2 Therapeutics

ANTX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,641

Bullish sentiment (50-day avg)100%

Price to earnings ratio-4.32

Market capitalization189.1M

Earnings per share-1.05

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-35.2M

Social

What share of all stock conversation is about ANTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Mar 18

AN2 Therapeutics, Inc. (ANTX) will present P1 Healthy Volunteers results in 1Q26 for AN2-502998.
NASDAQ:NXXT benefits from long-term demand, with fleet economics making the story feel very scalable.
NASDAQ:NXXT's operating base and addition of AI coordination make the story feel way more scalable, with grid stress and efficiency becoming critical.

Generated by AI

Sentiment

Of the messages about ANTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	86.13% +11.51
Bearish	0%	0%	0%	13.87% -11.51

Bullish· Mar 10

$ANTX has seen a significant increase in volume, with a 151 times higher trading volume than its average, indicating strong market activity.
A $40M private placement has fueled the company's clinical pipeline, driving the surge in stock price and making it a high-risk, high-reward biotech play.
The stock has broken out to $5.25, up 84.21%, and is expected to continue its momentum, with some analysts monitoring for institutional accumulation.

Bearish· Mar 10

$ANTX is headed to $4 and below, with the stock price potentially dropping to $4 and below.
The stock is experiencing a blow off top action, with a near 7x increase in 4 trading days, making it a good short opportunity if it can stay below $5.25.
$ANTX is experiencing heavy selling pressure, with a lack of buyers at $4.85 and a large volume of sellers looking to get rid of the stock, potentially leading to a drop to $4 or lower.

Generated by AI

Topics

Of the messages about ANTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	98.72%	52.8%
Analysts	50%	50%	1.28%	10.51%
Controversies	0%	0%	0%	1.4%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	9.58%
Technical Analysis	0%	0%	0%	25.7%

Announcements· Mar 10

AN2 Therapeutics, Inc. (ANTX) has announced a $40 million private placement financing, selling 8.245 million shares and 5.789 million pre-funded warrants.
The private placement is expected to fuel the company's clinical pipeline and drive growth, with a significant capital infusion and strong institutional backing.
The stock has surged to $5.25, up 84.21%, following the announcement, with aggressive buyers driving the volume spike and institutional accumulation being monitored.

Technical Analysis· Mar 9

$ANTX is forming a pennant and is poised to break out at $5.70, with volume and momentum indicating a potential move.
The stock has shown strong relative strength versus the market, holding gains while others chop, indicating a bullish sign.
$ANTX is showing signs of a potential squeeze on the daily time frame, with a top watch at the current price, and is also targeting an entry point at $5.45 with a potential move to $7.15.

Generated by AI

Community

Of the messages about ANTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	96.34%	11.8%
Newcomers	100%	100%	3.66%	88.2%

Mar 10

Newcomers to the $ANTX stock are excited about the potential for growth in private LTE networks, driven by demand from energy, government, and the 5G surge.
Investors are watching for key partnerships and contracts that could propel AN2 Therapeutics forward, making it a promising stock for their portfolios.
The company's recent $40M private placement and upcoming clinical pipeline developments are fueling a surge in the stock price, with many expecting continued momentum.

Generated by AI

News

AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research

AN2 Therapeutics (ANTX) has received extended funding from the Gates Foundation for its tuberculosis

2d agoYahoo Finance

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco

29d agoYahoo Finance

Also Discussed

Investors talking about ANTX also mention

#	Name	Attention
1	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
2	KRON - Kronos Bio, Inc.	——
3	Jade Biosciences Inc.AVTE	0%0
4	RAPT - RAPT Therapeutics, Inc.	——
5	Rallybio Corp.RLYB	0%0
6	PepGen Inc.PEPG	0%new
7	BioAffinity Technologies Inc.BIAF	0%+0
8	Roma Green Finance LimitedROMA	0%0
9	Highwoods Properties, Inc.HIW	0%new
10	MKDWELL Tech Inc.MKDW	0%+0

AN2 Therapeutics, Inc.

Healthcare
Biotechnology

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s current pipeline includes programs in infectious diseases, hematologic disorders, and oncology, with research efforts aimed at addressing serious and rare conditions with high unmet medical needs. Its product candidates include oral therapies under development for diseases such as Chagas disease, non-tuberculous mycobacterial lung disease, and other infectious disease targets, alongside earlier-stage oncology and global health programs. AN2 Therapeutics operates as a drug discovery and development business, advancing its candidates through preclinical and clinical studies to support potential future therapies for patients and healthcare providers.

Website

Location

1300 El Camino Real

Menlo Park, CA, 94025

United States

Social

What share of all stock conversation is about ANTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Mar 18

AN2 Therapeutics, Inc. (ANTX) will present P1 Healthy Volunteers results in 1Q26 for AN2-502998.
NASDAQ:NXXT benefits from long-term demand, with fleet economics making the story feel very scalable.
NASDAQ:NXXT's operating base and addition of AI coordination make the story feel way more scalable, with grid stress and efficiency becoming critical.

Generated by AI

Sentiment

Of the messages about ANTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	86.13% +11.51
Bearish	0%	0%	0%	13.87% -11.51

Bullish· Mar 10

$ANTX has seen a significant increase in volume, with a 151 times higher trading volume than its average, indicating strong market activity.
A $40M private placement has fueled the company's clinical pipeline, driving the surge in stock price and making it a high-risk, high-reward biotech play.
The stock has broken out to $5.25, up 84.21%, and is expected to continue its momentum, with some analysts monitoring for institutional accumulation.

Bearish· Mar 10

$ANTX is headed to $4 and below, with the stock price potentially dropping to $4 and below.
The stock is experiencing a blow off top action, with a near 7x increase in 4 trading days, making it a good short opportunity if it can stay below $5.25.
$ANTX is experiencing heavy selling pressure, with a lack of buyers at $4.85 and a large volume of sellers looking to get rid of the stock, potentially leading to a drop to $4 or lower.

Generated by AI

Topics

Of the messages about ANTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	98.72%	52.8%
Analysts	50%	50%	1.28%	10.51%
Controversies	0%	0%	0%	1.4%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	9.58%
Technical Analysis	0%	0%	0%	25.7%

Announcements· Mar 10

AN2 Therapeutics, Inc. (ANTX) has announced a $40 million private placement financing, selling 8.245 million shares and 5.789 million pre-funded warrants.
The private placement is expected to fuel the company's clinical pipeline and drive growth, with a significant capital infusion and strong institutional backing.
The stock has surged to $5.25, up 84.21%, following the announcement, with aggressive buyers driving the volume spike and institutional accumulation being monitored.

Technical Analysis· Mar 9

$ANTX is forming a pennant and is poised to break out at $5.70, with volume and momentum indicating a potential move.
The stock has shown strong relative strength versus the market, holding gains while others chop, indicating a bullish sign.
$ANTX is showing signs of a potential squeeze on the daily time frame, with a top watch at the current price, and is also targeting an entry point at $5.45 with a potential move to $7.15.

Generated by AI

Community

Of the messages about ANTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	96.34%	11.8%
Newcomers	100%	100%	3.66%	88.2%

Mar 10

Newcomers to the $ANTX stock are excited about the potential for growth in private LTE networks, driven by demand from energy, government, and the 5G surge.
Investors are watching for key partnerships and contracts that could propel AN2 Therapeutics forward, making it a promising stock for their portfolios.
The company's recent $40M private placement and upcoming clinical pipeline developments are fueling a surge in the stock price, with many expecting continued momentum.

Generated by AI

AN2 Therapeutics

Social

Mar 18

Bullish· Mar 10

Bearish· Mar 10

Announcements· Mar 10

Technical Analysis· Mar 9

Mar 10

AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver (NASDAQ:ANTX)

An2 therapeutics director Robin Readnour sells $6,674 in shares

An2 therapeutics director Robin Readnour sells $97,322 in shares

An2 therapeutics director buys $11,601 in common stock

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Also Discussed

AN2 Therapeutics, Inc.

Company Information

Location

AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver (NASDAQ:ANTX)

An2 therapeutics director Robin Readnour sells $6,674 in shares

An2 therapeutics director Robin Readnour sells $97,322 in shares

An2 therapeutics director buys $11,601 in common stock

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Also Discussed

Social

Mar 18

Bullish· Mar 10

Bearish· Mar 10

Announcements· Mar 10

Technical Analysis· Mar 9

Mar 10